{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:17:27Z","timestamp":1793650647315,"version":"4.5.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T00:00:00Z","timestamp":1688515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T00:00:00Z","timestamp":1688515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HU21C0161"],"award-info":[{"award-number":["HU21C0161"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2021R1A2C2093916"],"award-info":[{"award-number":["NRF-2021R1A2C2093916"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2018R1A6A1A03023718"],"award-info":[{"award-number":["NRF-2018R1A6A1A03023718"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2018M3C7A1021858"],"award-info":[{"award-number":["NRF-2018M3C7A1021858"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2021R1A2C1013247"],"award-info":[{"award-number":["NRF-2021R1A2C1013247"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Alzheimer\u2019s disease (AD) is characterized by misfolding, oligomerization, and accumulation of amyloid-\u03b2 (A\u03b2) peptides in the brain. A\u03b2 monomers transform into A\u03b2 oligomers, which are toxic species, inducing tau hyperphosphorylation and the downstream effects on microglia and astrocytes, triggering synaptic and cognitive dysfunctions. The oligomers then deposit into A\u03b2 plaques, primarily composed of \u03b2-stranded fibrils, required for definitive AD diagnosis. As amyloid burden plays the pivotal role in AD pathogenesis, many efforts are devoted in preventing amyloidosis as a therapeutic approach to impede the disease progression. Here, we discovered carprofen, a non-steroidal anti-inflammatory drug, accelerates A\u03b2 aggregating into fibrils and increases A\u03b2 plaques when intraperitoneally injected to 5XFAD transgenic mouse model. However, the drug seems to alleviate the key Alzheimer-like phenotypes induced by A\u03b2 aggregation as we found attenuated neuroinflammation, improved post-synaptic density expression, associated with synaptic plasticity, and decreased phosphorylated tau levels. Carprofen also rescued impaired working memory as we discovered improved spontaneous alternation performance through Y-maze test assessed with A\u03b2(1\u201342)-infused mouse model. Collectively, while carprofen accelerates the conversion of A\u03b2 monomers into fibrils in vitro, the drug ameliorates the major pathological hallmarks of AD in vivo.<\/jats:p>","DOI":"10.1038\/s41598-023-36167-4","type":"journal-article","created":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T11:08:26Z","timestamp":1688555306000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Carprofen alleviates Alzheimer-like phenotypes of 5XFAD transgenic mice by targeting the pathological hallmarks induced by amyloid-\u03b2 aggregation"],"prefix":"10.1038","volume":"13","author":[{"given":"Donghee","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Eun","family":"Ryoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seungpyo","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3757-5652","authenticated-orcid":false,"given":"Hye Yun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5029-7082","authenticated-orcid":false,"given":"YoungSoo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,5]]},"reference":[{"key":"36167_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41582-019-0281-2","volume":"16","author":"SM Greenberg","year":"2020","unstructured":"Greenberg, S. M. et al. Cerebral amyloid angiopathy and Alzheimer disease\u2014one peptide, two pathways. Nat. Rev. Neurol. 16, 30\u201342 (2020).","journal-title":"Nat. Rev. Neurol."},{"key":"36167_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41582-018-0116-6","volume":"15","author":"F Panza","year":"2019","unstructured":"Panza, F., Lozupone, M., Logroscino, G. & Imbimbo, B. P. A critical appraisal of amyloid-beta-targeting therapies for Alzheimer disease. Nat. Rev. Neurol. 15, 73\u201388 (2019).","journal-title":"Nat. Rev. Neurol."},{"key":"36167_CR3","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/s41467-017-00579-4","volume":"8","author":"RF Sowade","year":"2017","unstructured":"Sowade, R. F. & Jahn, T. R. Seed-induced acceleration of amyloid-beta mediated neurotoxicity in vivo. Nat. Commun. 8, 512. https:\/\/doi.org\/10.1038\/s41467-017-00579-4 (2017).","journal-title":"Nat. Commun."},{"key":"36167_CR4","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.celrep.2014.02.031","volume":"7","author":"N Salvadores","year":"2014","unstructured":"Salvadores, N., Shahnawaz, M., Scarpini, E., Tagliavini, F. & Soto, C. Detection of misfolded Abeta oligomers for sensitive biochemical diagnosis of Alzheimer\u2019s disease. Cell Rep. 7, 261\u2013268. https:\/\/doi.org\/10.1016\/j.celrep.2014.02.031 (2014).","journal-title":"Cell Rep."},{"key":"36167_CR5","doi-asserted-by":"publisher","first-page":"a006338","DOI":"10.1101\/cshperspect.a006338","volume":"2","author":"L Mucke","year":"2012","unstructured":"Mucke, L. & Selkoe, D. J. Neurotoxicity of amyloid beta-protein: Synaptic and network dysfunction. Cold Spring Harb. Perspect. Med. 2, a006338. https:\/\/doi.org\/10.1101\/cshperspect.a006338 (2012).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"36167_CR6","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.neuron.2004.09.010","volume":"44","author":"DM Walsh","year":"2004","unstructured":"Walsh, D. M. & Selkoe, D. J. Deciphering the molecular basis of memory failure in Alzheimer\u2019s disease. Neuron 44, 181\u2013193. https:\/\/doi.org\/10.1016\/j.neuron.2004.09.010 (2004).","journal-title":"Neuron"},{"key":"36167_CR7","doi-asserted-by":"publisher","first-page":"292","DOI":"10.15698\/cst2018.11.162","volume":"2","author":"H Steiner","year":"2018","unstructured":"Steiner, H., Fukumori, A., Tagami, S. & Okochi, M. Making the final cut: Pathogenic amyloid-beta peptide generation by gamma-secretase. Cell Stress 2, 292\u2013310. https:\/\/doi.org\/10.15698\/cst2018.11.162 (2018).","journal-title":"Cell Stress"},{"key":"36167_CR8","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1039\/C6CS00731G","volume":"46","author":"SJ Lee","year":"2017","unstructured":"Lee, S. J., Nam, E., Lee, H. J., Savelieff, M. G. & Lim, M. H. Towards an understanding of amyloid-beta oligomers: Characterization, toxicity mechanisms, and inhibitors. Chem. Soc. Rev. 46, 310\u2013323 (2017).","journal-title":"Chem. Soc. Rev."},{"key":"36167_CR9","doi-asserted-by":"publisher","first-page":"160696","DOI":"10.1098\/rsos.160696","volume":"4","author":"C Xue","year":"2017","unstructured":"Xue, C., Lin, T. Y. W., Chang, D. & Guo, Z. F. Thioflavin T as an amyloid dye: Fibril quantification, optimal concentration and effect on aggregation. R. Soc. Open Sci. 4, 160696. https:\/\/doi.org\/10.1098\/rsos.160696 (2017).","journal-title":"R. Soc. Open Sci."},{"key":"36167_CR10","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/j.1749-6632.2000.tb06915.x","volume":"920","author":"C Sturchler-Pierrat","year":"2000","unstructured":"Sturchler-Pierrat, C. & Staufenbiel, M. Pathogenic mechanisms of Alzheimer\u2019s disease analyzed in the APP23 transgenic mouse model. Ann. N. Y. Acad. Sci. 920, 134\u2013139. https:\/\/doi.org\/10.1111\/j.1749-6632.2000.tb06915.x (2000).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"36167_CR11","doi-asserted-by":"publisher","first-page":"e89454","DOI":"10.1371\/journal.pone.0089454","volume":"9","author":"S Bhattacharya","year":"2014","unstructured":"Bhattacharya, S., Haertel, C., Maelicke, A. & Montag, D. Galantamine slows down plaque formation and behavioral decline in the 5XFAD mouse model of Alzheimer\u2019s disease. PLoS ONE 9, e89454. https:\/\/doi.org\/10.1371\/journal.pone.0089454 (2014).","journal-title":"PLoS ONE"},{"key":"36167_CR12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1750-1326-9-33","volume":"9","author":"V Landel","year":"2014","unstructured":"Landel, V. et al. Temporal gene profiling of the 5XFAD transgenic mouse model highlights the importance of microglial activation in Alzheimer\u2019s disease. Mol. Neurodegener. 9, 33. https:\/\/doi.org\/10.1186\/1750-1326-9-33 (2014).","journal-title":"Mol. Neurodegener."},{"key":"36167_CR13","doi-asserted-by":"publisher","first-page":"427","DOI":"10.3389\/fnmol.2017.00427","volume":"10","author":"RE Gonzalez-Reyes","year":"2017","unstructured":"Gonzalez-Reyes, R. E., Nava-Mesa, M. O., Vargas-Sanchez, K., Ariza-Salamanca, D. & Mora-Munoz, L. Involvement of astrocytes in Alzheimer\u2019s disease from a neuroinflammatory and oxidative stress perspective. Front. Mol. Neurosci. 10, 427 (2017).","journal-title":"Front. Mol. Neurosci."},{"key":"36167_CR14","doi-asserted-by":"publisher","first-page":"14299","DOI":"10.1523\/JNEUROSCI.3383-10.2010","volume":"30","author":"D Tampellini","year":"2010","unstructured":"Tampellini, D. et al. Effects of synaptic modulation on beta-amyloid, synaptophysin, and memory performance in Alzheimer\u2019s disease transgenic mice. J. Neurosci. 30, 14299\u201314304 (2010).","journal-title":"J. Neurosci."},{"key":"36167_CR15","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1093\/brain\/awaa223","volume":"143","author":"E Drummond","year":"2020","unstructured":"Drummond, E. et al. Phosphorylated tau interactome in the human Alzheimer\u2019s disease brain. Brain 143, 2803\u20132817. https:\/\/doi.org\/10.1093\/brain\/awaa223 (2020).","journal-title":"Brain"},{"key":"36167_CR16","doi-asserted-by":"publisher","DOI":"10.3791\/53308","author":"HY Kim","year":"2016","unstructured":"Kim, H. Y., Lee, D. K., Chung, B. R., Kim, H. V. & Kim, Y. Intracerebroventricular injection of amyloid-beta peptides in normal mice to acutely induce alzheimer-like cognitive deficits. J. Vis. Exp. https:\/\/doi.org\/10.3791\/53308 (2016).","journal-title":"J. Vis. Exp."},{"key":"36167_CR17","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/1750-1326-9-48","volume":"9","author":"S Tu","year":"2014","unstructured":"Tu, S., Okamoto, S., Lipton, S. A. & Xu, H. Oligomeric Abeta-induced synaptic dysfunction in Alzheimer\u2019s disease. Mol. Neurodegener. 9, 48. https:\/\/doi.org\/10.1186\/1750-1326-9-48 (2014).","journal-title":"Mol. Neurodegener."},{"key":"36167_CR18","doi-asserted-by":"publisher","first-page":"6777","DOI":"10.1038\/srep06777","volume":"4","author":"SM Cho","year":"2014","unstructured":"Cho, S. M. et al. Correlations of amyloid-beta concentrations between CSF and plasma in acute Alzheimer mouse model. Sci. Rep. 4, 6777. https:\/\/doi.org\/10.1038\/srep06777 (2014).","journal-title":"Sci. Rep."},{"key":"36167_CR19","doi-asserted-by":"publisher","first-page":"e0223697","DOI":"10.1371\/journal.pone.0223697","volume":"15","author":"I Hernandez-Avalos","year":"2020","unstructured":"Hernandez-Avalos, I. et al. Clinical evaluation of postoperative analgesia, cardiorespiratory parameters and changes in liver and renal function tests of paracetamol compared to meloxicam and carprofen in dogs undergoing ovariohysterectomy. PLoS ONE 15, e0223697. https:\/\/doi.org\/10.1371\/journal.pone.0223697 (2020).","journal-title":"PLoS ONE"},{"key":"36167_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14051045","author":"L Gomez-Segura","year":"2022","unstructured":"Gomez-Segura, L. et al. Swine as the animal model for testing new formulations of anti-inflammatory drugs: Carprofen pharmacokinetics and bioavailability of the intramuscular route. Pharmaceutics https:\/\/doi.org\/10.3390\/pharmaceutics14051045 (2022).","journal-title":"Pharmaceutics"},{"key":"36167_CR21","doi-asserted-by":"publisher","first-page":"8807","DOI":"10.1021\/jm3011146","volume":"55","author":"AD Favia","year":"2012","unstructured":"Favia, A. D. et al. Identification and characterization of carprofen as a multitarget fatty acid amide hydrolase\/cyclooxygenase inhibitor. J. Med. Chem. 55, 8807\u20138826 (2012).","journal-title":"J. Med. Chem."},{"key":"36167_CR22","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1111\/jvim.15897","volume":"34","author":"SM Jones","year":"2020","unstructured":"Jones, S. M. et al. The effect of combined carprofen and omeprazole administration on gastrointestinal permeability and inflammation in dogs. J. Vet. Intern. Med. 34, 1886\u20131893. https:\/\/doi.org\/10.1111\/jvim.15897 (2020).","journal-title":"J. Vet. Intern. Med."},{"key":"36167_CR23","doi-asserted-by":"publisher","first-page":"fcaa109","DOI":"10.1093\/braincomms\/fcaa109","volume":"2","author":"J Rivers-Auty","year":"2020","unstructured":"Rivers-Auty, J., Mather, A. E., Peters, R., Lawrence, C. B. & Brough, D. Anti-inflammatories in Alzheimer\u2019s disease-potential therapy or spurious correlate?. Brain Commun. 2, fcaa109. https:\/\/doi.org\/10.1093\/braincomms\/fcaa109 (2020).","journal-title":"Brain Commun."},{"key":"36167_CR24","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1124\/pr.56.3.3","volume":"56","author":"DL Simmons","year":"2004","unstructured":"Simmons, D. L., Botting, R. M. & Hla, T. Cyclooxygenase isozymes: The biology of prostaglandin synthesis and inhibition. Pharmacol. Rev. 56, 387\u2013437. https:\/\/doi.org\/10.1124\/pr.56.3.3 (2004).","journal-title":"Pharmacol. Rev."},{"key":"36167_CR25","doi-asserted-by":"publisher","first-page":"8997","DOI":"10.1038\/ncomms9997","volume":"6","author":"HY Kim","year":"2015","unstructured":"Kim, H. Y. et al. EPPS rescues hippocampus-dependent cognitive deficits in APP\/PS1 mice by disaggregation of amyloid-beta oligomers and plaques. Nat. Commun. 6, 8997. https:\/\/doi.org\/10.1038\/ncomms9997 (2015).","journal-title":"Nat. Commun."},{"key":"36167_CR26","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/s0197-4580(01)00299-8","volume":"22","author":"GP Lim","year":"2001","unstructured":"Lim, G. P. et al. Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol. Aging 22, 983\u2013991. https:\/\/doi.org\/10.1016\/s0197-4580(01)00299-8 (2001).","journal-title":"Neurobiol. Aging"},{"key":"36167_CR27","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1159\/000078501","volume":"23","author":"CA Szekely","year":"2004","unstructured":"Szekely, C. A. et al. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer\u2019s disease: A systematic review. Neuroepidemiology 23, 159\u2013169. https:\/\/doi.org\/10.1159\/000078501 (2004).","journal-title":"Neuroepidemiology"},{"key":"36167_CR28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3390\/ijms22158185","volume":"22","author":"PP Guan","year":"2021","unstructured":"Guan, P. P., Yang, L. Q., Xu, G. B. & Wang, P. Indomethacin disrupts the formation of beta-amyloid plaques via an alpha2-macroglobulin-activating lrp1-dependent mechanism. Int. J. Mol. Sci. 22, 25. https:\/\/doi.org\/10.3390\/ijms22158185 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"36167_CR29","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3233\/JAD-130275","volume":"36","author":"M Manczak","year":"2013","unstructured":"Manczak, M. & Reddy, P. H. Abnormal interaction of oligomeric amyloid-beta with phosphorylated tau: Implications to synaptic dysfunction and neuronal damage. J. Alzheimer\u2019s Dis. 36, 285\u2013295. https:\/\/doi.org\/10.3233\/JAD-130275 (2013).","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"36167_CR30","doi-asserted-by":"publisher","first-page":"975","DOI":"10.3233\/JAD-160612","volume":"57","author":"R Rajmohan","year":"2017","unstructured":"Rajmohan, R. & Reddy, P. H. Amyloid-beta and phosphorylated tau accumulations cause abnormalities at synapses of alzheimer\u2019s disease neurons. J. Alzheimer\u2019s Dis. 57, 975\u2013999. https:\/\/doi.org\/10.3233\/JAD-160612 (2017).","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"36167_CR31","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.7150\/ijbs.57078","volume":"17","author":"H Zhang","year":"2021","unstructured":"Zhang, H. et al. Interaction between Abeta and Tau in the pathogenesis of alzheimer\u2019s disease. Int. J. Biol. Sci. 17, 2181\u20132192. https:\/\/doi.org\/10.7150\/ijbs.57078 (2021).","journal-title":"Int. J. Biol. Sci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-36167-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-36167-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-36167-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T11:15:17Z","timestamp":1688555717000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-36167-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,5]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["36167"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-36167-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,5]]},"assertion":[{"value":"27 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"10889"}}